Management of Severe Hypertriglyceridemia Due to Lipoprotein Lipase Deficiency in Children

Total Page:16

File Type:pdf, Size:1020Kb

Management of Severe Hypertriglyceridemia Due to Lipoprotein Lipase Deficiency in Children ID: 19-0052 -19-0052 S W Y Poon and others Management of severe ID: 19-0052; July 2019 hypertriglyceridemia DOI: 10.1530/EDM-19-0052 Management of severe hypertriglyceridemia due to lipoprotein lipase deficiency in children Correspondence Sarah W Y Poon, Karen K Y Leung and Joanna Y L Tung should be addressed to J Y L Tung Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Email Hong Kong [email protected] Summary Severe hypertriglyceridemia is an endocrine emergency and is associated with acute pancreatitis and hyperviscosity syndrome.Wedescribeaninfantwithlipoproteinlipasedeficiencywithseverehypertriglyceridemiawhopresentedwith acute pancreatitis. She was managed acutely with fasting and intravenous insulin infusion, followed by low-fat diet with no pharmacologicalagent.Subsequentfollow-upuntiltheageof5 yearsshowedsatisfactorylipidprofileandshehasnormal growth and development. Learning points: • Hypertriglyceridemia-inducedacutepancreatitishassignificantmorbidityandmortality,andprompttreatmentis imperative. • Whennosecondarycausesarereadilyidentified,geneticevaluationshouldbepursuedinhypertriglyceridemiain children. • Intravenousinsulinisasafeandeffectiveacutetreatmentforhypertriglyceridemiainchildren,evenininfants. • Long-termmanagementwithdietarymodificationsalonecouldbeeffectiveforprimaryhypertriglyceridemiadue tolipoproteinlipasedeficiency,atleastinearlychildhoodphase. Background Hypertriglyceridemia is defined as fasting plasma The clinical severity and rate of complications with triglyceride (TG) level above an age and gender – adjusted hypertriglyceridemic pancreatitis are generally higher, 95th percentile. Monogenic hypertriglyceridemia include thus appropriate treatment and prevention of disease genetic defects in triglyceride metabolism, whereas recurrence is essential. As such, there is no consensus polygenic hypertriglyceridemia are often due to interplay on the acute and long-term management of severe between genetic, hormonal and environmental factors hypertriglyceridemia in the pediatric population. Our including uncontrolled diabetes, obesity, metabolic case highlights the use of insulin as an adjunct to lower syndrome and medications in the pediatric age group. the TG, followed by medium-chain triglyceride (MCT)- Severe hypertriglyceridemia, defined as triglyceride based diet, and subsequently, strict dietary fat restrictions concentration of greater than 1000 mg/dL, can present as long-term management in a young infant with familial with pancreatitis in the first decade of life and should chylomicronemia syndrome (FCS) due to lipoprotein prompt consideration of monogenic hypertriglyceridemia. lipase (LPL) deficiency. This work is licensed under a Creative Commons © 2019 The authors https://edm.bioscientifica.com/ Attribution-NonCommercial-NoDerivatives 4.0 PublishedbyBioscientificaLtd International License. Downloaded from Bioscientifica.com at 09/28/2021 07:39:27PM via free access S W Y Poon and others Management of severe ID: 19-0052; July 2019 hypertriglyceridemia DOI: 10.1530/EDM-19-0052 Case presentation compatible with type I hyperlipidemia with LPL deficiency. Subsequent genetic testing confirmed two heterozygous A 38-day-old Chinese girl presented to the emergency LPL variants, p.Cys54 (p.Cys27 in mature protein) (C27X) department for vomiting, irritability and suspected and p.Leu279Val (L279V), which have been reported to seizure. She was born full term with a birth weight of be pathogenic mutations (1, 2). Parents declined genetic 2.8 kg with uneventful postnatal course. She was on studies due to personal reasons. mixed feeding (breast milk supplemented with normal formula) and was growing along the 25th centile. Her parents are non-consanguineous Chinese and her father Treatment has hypertriglyceridemia with triglyceride (TG) level at She was kept fasted and started on intravenous dextrose. 250–300 mg/dL and diabetes mellitus requiring TG level dropped to 9232 mg/dL after 11 h of fasting. medication since the age of 40 years. There is otherwise Intravenous insulin infusion was then started at no family history of dyslipidemia or pancreatitis. 0.05 unit/kg/h around 12 h after admission. TG level On admission, she was noted to have decreased slowly to 106 mg/dL after 84 h before the hepatosplenomegaly. Physical examination was infusion was stopped. Octreotide infusion at 0.3 µg/kg/h unremarkable otherwise and there were no skin lesions was started for acute pancreatitis and serum lipase or abnormal body fat distribution. During venesection, gradually normalized (Fig. 2). milky serum was noted (Fig. 1A and B). Feeding was resumed after 1 week of fasting with Monogen, a low-fat, high-MCT infant milk formula Investigation (84% MCT, 16% long-chain triglyceride) containing 12.9 g fat per 100 g, with total fat intake of 9–12 g per day. TG levels were found to be >13,290 mg/dL with the total cholesterol level at 919 mg/dL. Serum lipase was elevated at 2534 µ/L (normal 23–300 µ/L), while amylase level Outcome and follow-up was normal. Serum sodium was 129 mEq/L, potassium She recovered uneventfully and weaning diet was started 5.1 mEq/L, adjusted calcium 8.12 mg/dL and bicarbonate at 6 months of age with low-fat diet (fat calorie 15% of 18 mEq/L. Computed tomography of the abdomen total calories). Until the age of 5 years, triglyceride level showed indistinct pancreatic head with loss of glandular was maintained at 195–265 mg/dL, while high-density structure, while the uncinated process, pancreatic body lipoprotein cholesterol remained low at 11.5–19 mg/dL. and tail displayed homogenous enhancement, suggestive She was later found to have mild vitamin D deficiency of pancreatitis. and was put on calciferol supplement, while vitamin B12, Agarose gel electrophoresis showed a dense folate and zinc levels were satisfactory and clotting profile chylomicron band, while the intensity of the very low- was normal. density lipoprotein (VLDL) band was mildly increased, There were no further episodes of acute pancreatitis. Her growth is along the 25th centile and she has normal development. Discussion We describe an infant who had acute pancreatitis resulting from hypertriglyceridemia due to LPL deficiency, the most common cause of FCS. Other mutations include apolipoprotein C2 (APOC2), apolipoprotein A5 (APOA5), glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GP1HBP1) and lipase maturation factor 1 (LMF1), which are important co-factors of LPL. LPL hydrolyzes triglyceride of chylomicrons and VLDLs after fat intake. Mutation in genes encoding LPL Figure 1 and its co-factors thus result in impaired lipolytic cascade (A and B) Milky serum noted on blood taking. and accumulation of chylomicrons in the plasma. https://edm.bioscientifica.com/ 2 Downloaded from Bioscientifica.com at 09/28/2021 07:39:27PM via free access S W Y Poon and others Management of severe ID: 19-0052; July 2019 hypertriglyceridemia DOI: 10.1530/EDM-19-0052 Triglyceride level with time 13290 14000 Insulin infusion started 12000 ) 10000 9232 8000 6000 4000 TG level (mg/dL Insulin infusion stopped 1656 1506 2000 549 124 106 0 0612 18 24 30 36 42 48 54 60 66 72 78 84 90 Time (Hour) Figure 2 Trend of triglyceride level with time after treatment initiated. As in our patient, affected individuals typically degradation into fatty acid and glycerol and facilitates present with lipemia plasma during blood sampling. storage in adipocytes (3). Therefore, insulin would only While abdominal pain is suggestive of pancreatitis in be useful if there is residual LPL activity. In a number older children, presentation during infancy is non- of case reports in adults, insulin has been shown to be specific and heterogeneous. Other physical findings effective in reducing TG levels. However, case report on may include eruptive xanthomas, lipemic retinitis and insulin use in patients with FCS, in particular due to hepatosplenomegaly, but it may not be present in all LPL deficiency, is limited. While our case demonstrated cases and could be non-specific. Due to interference by sustained decline in TG level with insulin infusion, one markedly elevated plasma triglyceride level, amylase cannot ascertain if similar effect could be achieved by level may be spuriously normal even with pancreatitis. fasting alone. Indeed, functional data related to both Thus, measurement of serum lipase level is essential in L279V and C27X mutations are limited. Theoretically, this situation. C27X creates a premature termination in the translation Management of hypertriglyceridemia in children is of the LPL peptide, and the very short truncated peptide challenging as there is lack of established guideline. with only 26 amino acids is expected to carry no As such, we aim to review the acute and long-term catalytic function (2). Therefore, insulin may have only management in children. contributed modest effect in our case. However, at the initial presentation, such information was not available. The clinical decision to initiate insulin infusion was Acute management mainly based on the balance between the potential risks Fasting and benefits. Intravenous insulin given as continuous Since chylomicrons are produced in the small intestine infusion, at 0.1–0.3 units/kg/h, allows easier titration and are dependent on dietary fat for formation, fasting of doses compared to subcutaneous boluses. The major results in robust decline in TG levels and allows gradual risk with intravenous insulin, especially in
Recommended publications
  • Case Report: Eruptive Xanthoma in a 14-Year-Old Boy Ryan M
    Case Report: Eruptive Xanthoma in a 14-year-old boy Ryan M. Proctor, DO; Warren A. Peterson, DO; Michael W. Peterson, DO: Michael R. Proctor, DO; J. Ryan Jackson, DO; Andrew C. Duncanson OMS4; Allen E. Stout, DC. Dr. R. Proctor, Dr. W. Peterson, Dr. M. Peterson are from Aspen Dermatology Residency, Spanish Fork, UT; Dr. M. Proctor is from Arizona Desert Dermatology, Kingman, AZ; Dr. Jackson is from Sampson Regional Medical Center, Clinton, NC; OMS4 Duncanson is from Des Moines University, Des Moines, IA; DC Stout is from Stout Wellness Center, Fort Mohave, AZ. INTRODUCTION CLINICAL PHOTOS DISCUSSION Xanthomas are benign collections of lipid deposits that manifest as yellow to Eruptive xanthomas (EX) are often an indicator of severe red firm papules, nodules, or plaques. This yellow/red coloration is due to the hypertriglyceridemia and can indicate undiagnosed or Figure 1 Figure 2 carotene in lipids. Xanthomas are composed of lipid filled macrophages decompensated diabetes mellitus (DM).1 The triglyceride levels in known as “foam cells”. Xanthomas can be due to genetic disorders of lipid these patients can be >3000-4000 mg/dl (normal <150 mg/dl).2 metabolism, such as autosomal dominant hypocholesteremia or familial lipoprotein lipase(LPL) deficiency.1,2 They can also be caused by severe It is important to quickly diagnose and manage these patients due hypertriglyceridemia and have been associated with undiagnosed diabetic to the possible sequela of diabetes mellitus and hyperlipidemia. dyslipidemia, hypothyroidism, cholestasis, nephrotic
    [Show full text]
  • Genetic Testing for Familial Hypercholesterolemia AHS – M2137
    Corporate Medical Policy Genetic Testing for Familial Hypercholesterolemia AHS – M2137 File Name: genetic_testing_for_familial_hypercholesterolemia Origination: 01/01/2019 Last CAP Review: 07/2021 Next CAP Review: 07/2022 Last Review: 07/2021 Description of Procedure or Service Definitions Familial hypercholesterolemia (FH) is a genetic condition that results in premature atherosclerotic cardiovascular disease due to lifelong exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels (Sturm et al., 2018). FH encompasses multiple clinical phenotypes associated with distinct molecular etiologies. The most common is an autosomal dominant disorder caused by mutations in one of three genes, low-density lipoprotein receptor (LDLR), apolipoprotein B-100 (APOB), and proprotein convertase subtilisin-like kexin type 9 (PCSK9) (Ahmad et al., 2016; Goldberg et al., 2011). Rare autosomal recessive disease results from mutation in low-density lipoprotein receptor adaptor protein (LDLRAP) (Garcia et al., 2001). Related Policies Cardiovascular Disease Risk Assessment AHS – G2050 ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for genetic testing for familial hypercholesterolemia when it is determined the medical criteria or reimbursement guidelines below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. When Genetic Testing for Familial Hypercholesterolemia is covered 1. Genetic testing to establish a molecular diagnosis of Familial Hypercholesterolemia is considered medically necessary when BOTH of the following criteria are met: A.
    [Show full text]
  • Apoa5genetic Variants Are Markers for Classic Hyperlipoproteinemia
    CLINICAL RESEARCH CLINICAL RESEARCH www.nature.com/clinicalpractice/cardio APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia 1 1 1 2 2 1 1 Jian Wang , Matthew R Ban , Brooke A Kennedy , Sonia Anand , Salim Yusuf , Murray W Huff , Rebecca L Pollex and Robert A Hegele1* SUMMARY INTRODUCTION Hypertriglyceridemia is a common biochemical Background Several known candidate gene variants are useful markers for diagnosing hyperlipoproteinemia. In an attempt to identify phenotype that is observed in up to 5% of adults. other useful variants, we evaluated the association of two common A plasma triglyceride concentration above APOA5 single-nucleotide polymorphisms across the range of classic 1.7 mmol/l is a defining component of the meta­ 1 hyperlipoproteinemia phenotypes. bolic syndrome and is associated with several comorbidities, including increased risk of cardio­ Methods We assessed plasma lipoprotein profiles and APOA5 S19W and vascular disease2 and pancreatitis.3,4 Factors, –1131T>C genotypes in 678 adults from a single tertiary referral lipid such as an imbalance between caloric intake and clinic and in 373 normolipidemic controls matched for age and sex, all of expenditure, excessive alcohol intake, diabetes, European ancestry. and use of certain medications, are associated Results We observed significant stepwise relationships between APOA5 with hypertriglyceridemia; however, genetic minor allele carrier frequencies and plasma triglyceride quartiles. The factors are also important.5,6 odds ratios for hyperlipoproteinemia types 2B, 3, 4 and 5 in APOA5 S19W Complex traits, such as plasma triglyceride carriers were 3.11 (95% CI 1.63−5.95), 4.76 (2.25−10.1), 2.89 (1.17−7.18) levels, usually do not follow Mendelian patterns of and 6.16 (3.66−10.3), respectively.
    [Show full text]
  • Lipodystrophy Due to Adipose Tissue Specific Insulin Receptor
    Page 1 of 50 Diabetes Lipodystrophy Due to Adipose Tissue Specific Insulin Receptor Knockout Results in Progressive NAFLD Samir Softic1,2,#, Jeremie Boucher1,3,#, Marie H. Solheim1,4, Shiho Fujisaka1, Max-Felix Haering1, Erica P. Homan1, Jonathon Winnay1, Antonio R. Perez-Atayde5, and C. Ronald Kahn1. 1 Section on Integrative Physiology and Metabolism, Joslin Diabetes Center and Department of Medicine, Harvard Medical School, Boston, MA 2 Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, MA 3 Cardiovascular and Metabolic Diseases iMed, AstraZeneca R&D, 431 83 Mölndal, Sweden (current address) 4 KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway 5 Department of Pathology, Boston Children’s Hospital, and Harvard Medical School, Boston, MA # These authors contributed equally to this work. Corresponding author: C. Ronald Kahn, MD Joslin Diabetes Center One Joslin Place Boston, MA 02215 Phone: (617)732-2635 Fax:(617)732-2487 E-mail: [email protected] Keywords: Insulin receptors, IGF-1 receptors, lipodystrophy, diabetes, dyslipidemia, fatty liver, liver tumor, NAFLD, NASH. Running title: Lipodystrophic mice develop progressive NAFLD 1 Diabetes Publish Ahead of Print, published online May 10, 2016 Diabetes Page 2 of 50 SUMMARY Ectopic lipid accumulation in the liver is an almost universal feature of human and rodent models of generalized lipodystrophy and also is a common feature of type 2 diabetes, obesity and metabolic syndrome. Here we explore the progression of fatty liver disease using a mouse model of lipodystrophy created by a fat-specific knockout of the insulin receptor (F-IRKO) or both IR and insulin-like growth factor-1 receptor (F- IR/IGF1RKO).
    [Show full text]
  • The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia: a Review
    Review Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.26.004382 The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia: A Review Alaa Abousetta, Ibrahim Abousetta, Theresa Dobler, Lia Ebrahimi, Vassillis Frangoullis, Stephanos Christodoulides and Ioannis Patrikios* School of Medicine, European University Cyprus, Cyprus *Corresponding author: Ioannis Patrikios, School of Medicine, European University Cyprus, Cyprus ARTICLE INFO Abstract Received: March 06, 2020 Hypertriglyceridemia is a common problem in adults in the developed world. It is associated with increased levels of triglycerides within the blood, which subsequently Published: March 17, 2020 promote the development of other diseases such as cardiovascular disease and pancreatitis. Triglycerides are mostly consumed through the diet and act as a source of energy in between meals. However, the levels of triglycerides increase proportionally Citation: Alaa A, Ibrahim A, Theresa D, Lia with the number of calories consumed. This only leads to a problem if the total daily E, Ioannis P, et al., The Effect of Omega-3 energy expenditure is exceeded. Additionally, the type of macronutrients taken in Fatty Acids on Hypertriglyceridemia: A Re- view. Biomed J Sci & Tech Res 26(4)-2020. for instance, high carbohydrate intake has been associated with an increased plasma BJSTR. MS.ID.004382. triglyceridethrough the level.diet has If thea direct levels influence of the triglycerideson having an inincreased the blood level rise of abovetriglycerides, 150 mg/ as Abbreviations: FHTG: Familial hypertri- dL, it is considered as hypertriglyceridemia. Increasing numbers of triglycerides can glyceridemia; FCH: Familial Combined Hy- have multiple underlying causes, which can be divided into primary and secondary perlipidemia, systemic lupus erythemato- causes.
    [Show full text]
  • Pathophysiology of Adipocyte Defects and Dyslipidemia in HIV Lipodystrophy: New Evidence from Metabolic and Molecular Studies
    American Journal of Infectious Diseases 2 (3): 167-172, 2006 ISSN 1553-6203 © 2006 Science Publications Pathophysiology of Adipocyte Defects and Dyslipidemia in HIV Lipodystrophy: New Evidence from Metabolic and Molecular Studies 1,6Ashok Balasubramanyam, 1,6Rajagopal V. Sekhar, 2,3Farook Jahoor 4Henry J. Pownall and 5Dorothy Lewis 1Translational Metabolism Unit, Division of Diabetes, Endocrinology and Metabolism, 2Department of Pediatrics, 3Children’s Nutrition Research Center 4Section of Atherosclerosis and Lipoprotein Metabolism, 5Department of Immunology Baylor College of Medicine; 6Endocrine Service, Ben Taub General Hospital, Houston, Texas Abstract: Despite a burgeoning mass of descriptive information regarding the epidemiology, clinical features, body composition changes, hormonal alterations and dyslipidemic patterns in patients with HIV lipodystrophy syndrome (HLS), the specific biochemical pathways that are dysregulated in the condition and the molecular mechanisms that lead to their dysfunction, remain relatively unexplored. In this paper, we review studies that detail the metabolic basis of the dyslipidemia - specifically, the hypertriglyceridemia - that is the serologic hallmark of HLS and present new data relevant to mechanisms of dyslipidemia in the postprandial state. We also describe preliminary experiments showing that in addition to the well-known effects of highly-active antiretroviral drugs, the functional disruption of adipocytes and preadipocytes by factors intrinsic to HIV-infected immunocytes may play a role in the pathogenesis of HLS. Key words: Triglycerides, cholesterol, lipoprotein lipase, lipolysis, lymphocyte INTRODUCTION Metabolic basis of HLS - studies in the fasting and fed state: Whole body kinetic studies have Characteristics of dyslipidemia and its relationship demonstrated defects in specific lipid metabolic [19-21] to lipodystrophy: A characteristic dyslipidemic pattern pathways in HLS patients in both the fasting and observed in the majority of patients with HLS is fed (25) states.
    [Show full text]
  • Lipoprotein Lipase: a General Review Moacir Couto De Andrade Júnior1,2*
    Review Article iMedPub Journals Insights in Enzyme Research 2018 www.imedpub.com Vol.2 No.1:3 ISSN 2573-4466 DOI: 10.21767/2573-4466.100013 Lipoprotein Lipase: A General Review Moacir Couto de Andrade Júnior1,2* 1Post-Graduation Department, Nilton Lins University, Manaus, Amazonas, Brazil 2Department of Food Technology, Instituto Nacional de Pesquisas da Amazônia (INPA), Manaus, Amazonas, Brazil *Corresponding author: MC Andrade Jr, Post-Graduation Department, Nilton Lins University, Manaus, Amazonas, Brazil, Tel: +55 (92) 3633-8028; E-mail: [email protected] Rec date: March 07, 2018; Acc date: April 10, 2018; Pub date: April 17, 2018 Copyright: © 2018 Andrade Jr MC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Citation: Andrade Jr MC (2018) Lipoprotein Lipase: A General Review. Insights Enzyme Res Vol.2 No.1:3 Abstract Lipoprotein Lipase: Historical Hallmarks, Enzymatic Activity, Characterization, and Carbohydrates (e.g., glucose) and lipids (e.g., free fatty acids or FFAs) are the most important sources of energy Present Relevance in Human for most organisms, including humans. Lipoprotein lipase (LPL) is an extracellular enzyme (EC 3.1.1.34) that is Pathophysiology and Therapeutics essential in lipoprotein metabolism. LPL is a glycoprotein that is synthesized and secreted in several tissues (e.g., Macheboeuf, in 1929, first described chemical procedures adipose tissue, skeletal muscle, cardiac muscle, and for the isolation of a plasma protein fraction that was very rich macrophages). At the luminal surface of the vascular in lipids but readily soluble in water, such as a lipoprotein [1].
    [Show full text]
  • Other Types of Primary Hyperlipoproteinemia
    82 Journal of Atherosclerosis and Thrombosis Vol.21, No.2 Committee Report 10 Other Types of Primary Hyperlipoproteinemia (Hyperlipidemia) Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan ― 2012 Version Tamio Teramoto, Jun Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida, Shinji Kihara, Makoto Kinoshita, Chizuko Maruyama, Takao Ohta, Tomonori Okamura, Shizuya Yamashita, Masayuki Yokode and Koutaro Yokote Committee for Epidemiology and Clinical Management of Atherosclerosis 1. Primary Hyperlipoproteinemias (Hyperlipidemias) enhanced hepatic apolipoprotein (apo) B-100 synthe- Other Than Familial Hypercholesterolemia sis, decreased LPL activity, increased very-low-density There are various types of primary hyperlipopro- lipoprotein (VLDL) secretion from the liver and the teinemias (hyperlipidemias) other than familial hyper- accumulation of visceral fat as factors for the develop- cholesterolemia (FH). These types are clinically ment of symptoms and has been reported to be related important and classified according to their associated to abnormalities of the LPL and APOC-Ⅱ genes or pathophysiology and genetic abnormalities (Table 1)1). APOA-Ⅰ/C-Ⅲ/A-Ⅳ gene cluster. However, none of Familial lipoprotein lipase (LPL) deficiency manifests these findings have been proven to be definitive. It has as severe hyperchylomicronemia and may present with also been suggested that FCHL is caused by a poly- eruptive cutaneous xanthomas or acute pancreatitis, genic background that tends to induce hyperlipopro- although it does not necessarily accompany atheroscle- teinemia due to environmental factors, such as over- rotic cardiovascular disease (CVD). On the other nutrition and a low level of physical activity.
    [Show full text]
  • Severe Hypertriglyceridemia in a Patient Heterozygous for a Lipoprotein Lipase Gene Allele with Two Novel Missense Variants
    European Journal of Human Genetics (2015) 23, 1259–1261 & 2015 Macmillan Publishers Limited All rights reserved 1018-4813/15 www.nature.com/ejhg SHORT REPORT Severe hypertriglyceridemia in a patient heterozygous for a lipoprotein lipase gene allele with two novel missense variants Ursula Kassner*,1, Bastian Salewsky2,3, Marion Wühle-Demuth1, Istvan Andras Szijarto1, Thomas Grenkowitz1, Priska Binner4, Winfried März4,5,6, Elisabeth Steinhagen-Thiessen1,2 and Ilja Demuth*,2,3 Rare monogenic hyperchylomicronemia is caused by loss-of-function mutations in genes involved in the catabolism of triglyceride-rich lipoproteins, including the lipoprotein lipase gene, LPL. Clinical hallmarks of this condition are eruptive xanthomas, recurrent pancreatitis and abdominal pain. Patients with LPL deficiency and severe or recurrent pancreatitis are eligible for the first gene therapy treatment approved by the European Union. Therefore the precise molecular diagnosis of familial hyperchylomicronemia may affect treatment decisions. We present a 57-year-old male patient with excessive hypertriglyceridemia despite intensive lipid-lowering therapy. Abdominal sonography showed signs of chronic pancreatitis. Direct DNA sequencing and cloning revealed two novel missense variants, c.1302A4T and c.1306G4A, in exon 8 of the LPL gene coexisting on the same allele. The variants result in the amino-acid exchanges p.(Lys434Asn) and p.(Gly436Arg). They are located in the carboxy-terminal domain of lipoprotein lipase that interacts with the glycosylphosphatidylinositol- anchored HDL-binding protein (GPIHBP1) and are likely of functional relevance. No further relevant mutations were found by direct sequencing of the genes for APOA5, APOC2, LMF1 and GPIHBP1. We conclude that heterozygosity for damaging mutations of LPL may be sufficient to produce severe hypertriglyceridemia and that chylomicronemia may be transmitted in a dominant manner, at least in some families.
    [Show full text]
  • Evaluation and Treatment of Hypertriglyceridemia: an Endocrine Society Clinical Practice Guideline
    SPECIAL FEATURE Clinical Practice Guideline Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline Lars Berglund, John D. Brunzell, Anne C. Goldberg, Ira J. Goldberg, Frank Sacks, Mohammad Hassan Murad, and Anton F. H. Stalenhoef University of California, Davis (L.B.), Sacramento, California 95817; University of Washington (J.D.B.), Seattle, Washington 98195; Washington University School of Medicine (A.C.G.), St. Louis, Missouri 63110; Columbia University (I.J.G.), New York, New York 10027; Harvard School of Public Health (F.S.), Boston, Massachusetts 02115; Mayo Clinic (M.H.M.), Rochester, Minnesota 55905; and Radboud University Nijmegen Medical Centre (A.F.H.S.), 6525 GA Nijmegen, The Netherlands Objective: The aim was to develop clinical practice guidelines on hypertriglyceridemia. Participants: The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Consensus Process: Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequen- tially by The Endocrine Society’s CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. Conclusions: The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150–999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hyper- triglyceridemia (triglycerides of Ͼ 1000 mg/dl) be considered a risk for pancreatitis.
    [Show full text]
  • Familial Partial Lipodystrophy
    Familial Partial Lipodystrophy Purvisha Patel; Ralph Starkey, MD; Michele Maroon, MD The lipodystrophies are rare disorders character- ized by insulin resistance and the absence or loss of body fat. The 4 subtypes of lipodystrophy are characterized by onset and distribution. Partial lipodystrophy is rare, with loss of fat from the extremities and excess fat accumulation in the face and neck; recognizing this phenotype and subsequent referral for endocrinologic care may improve outcome and reduce mortality. ipodystrophies are rare disorders characterized by insulin resistance and the absence or L loss of body fat.1 Classification of the 4 main subtypes of lipodystrophy is based on onset (congenital/familial vs acquired/sporadic) and dis- Figure not available online tribution (total/generalized vs partial). Congenital total lipodystrophy (also known as Berardinelli syndrome, Seip syndrome) is a rare autosomal- recessive disorder marked by an almost complete lack of adipose tissue from birth. Familial partial lipodystrophy (also known as Kobberling-Dunnigan syndrome) involves loss of subcutaneous fat from the extremities and accumulation of excess fat in the face and neck and to a lesser extent in the hands and feet. Acquired total lipodystrophy (also known as lipoatrophy, Lawrence-Seip syndrome) presents with generalized loss of fat beginning in childhood. Acquired partial lipodystrophy (also known as progressive lipodystrophy, partial lipoat- Figure 1. Accentuation of fat pads in the face and neck. rophy, Barraquer-Simons syndrome) is character- ized by loss of fat only from the upper extremities, face, and trunk.2 tional uterine bleeding (gravida 2, para 1, AB 1) Case Report necessitating total hysterectomy. On physical A 39-year-old white woman presented with the examination, accentuation of fat pads in the face complaint of thickened brown skin on the neck and and neck (Figure 1), central obesity, and prominent medial thighs.
    [Show full text]
  • Management of Hypertriglyceridemia BMJ: First Published As 10.1136/Bmj.M3109 on 12 October 2020
    STATE OF THE ART REVIEW Management of hypertriglyceridemia BMJ: first published as 10.1136/bmj.m3109 on 12 October 2020. Downloaded from Vinaya Simha ABSTRACT Hypertriglyceridemia is one of the most common lipid abnormalities encountered in clinical practice. Many monogenic disorders causing severe hypertriglyceridemia have been identified, but in most patients triglyceride elevations result from a Division of Endocrinology, Mayo combination of multiple genetic variations with small effects and environmental Clinic, Rochester, MN 55905, USA factors. Common secondary causes include obesity, uncontrolled diabetes, alcohol Correspondence to: misuse, and various commonly used drugs. Correcting these factors and optimizing [email protected] Cite this as: BMJ 2020;371:m3109 lifestyle choices, including dietary modification, is important before starting http://dx.doi.org/10.1136/bmj.m3109 drug treatment. The goal of drug treatment is to reduce the risk of pancreatitis in Series explanation: State of the Art Reviews are commissioned patients with severe hypertriglyceridemia and cardiovascular disease in those on the basis of their relevance with moderate hypertriglyceridemia. This review discusses the various genetic and to academics and specialists in the US and internationally. acquired causes of hypertriglyceridemia, as well as current management strategies. For this reason they are written predominantly by US authors. Evidence supporting the different drug and non-drug approaches to treating hypertriglyceridemia is examined, and an easy to adopt step-by-step management strategy is presented. Introduction independent risk factor for ASCVD and optimal drug Hypertriglyceridemia is a fairly common clinical treatment, including novel and emerging therapies, condition, but it continues to evoke considerable to mitigate this will be examined in greater detail.
    [Show full text]